Senolytic CAR T cells: what a mouse study reported
2024-01-24 · Reviewed 2026-10-07
A 2024 Nature Aging paper describes anti-uPAR CAR T cells in mice. It is not a human longevity trial and not a protocol.
Amor, Lowe, Sadelain and colleagues published this work in Nature Aging on 24 January 2024. The abstract is the source for every result on this page. The paper is not reproduced here.
Biological mechanism
The abstract describes CAR T cells aimed at uPAR, which the authors treat as a senescence-associated protein.
What was reported
uPAR-positive senescent cells accumulated during aging in the models they studied, and a single dose of the CAR T cells is described as having a lasting effect in those experiments.
Organism
Mouse. The abstract names aged mice, physiological aging, and mice on a high-fat diet.
Main results
The abstract reports improved exercise capacity and better glucose tolerance in those mouse settings. It does not report a human lifespan result.
Limitations
Animal experiments do not establish a human therapy. No human sample size is given.
Known risks
CAR T approaches used in medicine can be dangerous. This page does not explain how to make, buy, or use them.
What is still unproven
Whether any of these mouse findings hold in people, and whether clearing senescent cells is desirable in every tissue, is not answered here.
Scientific sources
- Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, Levine RL, Jones LW, Sadelain M, Lowe SW. Nature Aging, 2024-01-24. DOI 10.1038/s43587-023-00560-5
Educational information, not medical advice. This site does not publish experimental protocols for personal use and does not recommend genetic therapies, senolytics, or experimental drugs.